Palatin Technologies, Inc.

PTN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 14.1%, EPS fell 276.3% and free cash flow grew 34.2%, each against the same quarter a year earlier.

6.02 0.47 −7.24%
Market cap
$11.6M
P/E
0.0×
Fwd P/E
0.2×
Dividend yield
—
F-score
n/a
Altman Z
−67.72
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 4.19 0.00 0.00

+8 more quarters

P/S ratio
2.31 5.15 3.44 0.58
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.34) (15.43) (8.13) (4.75)
P/B ratio
4.56 6.43 3.41 19.43
EV/Sales
1.75 4.39 2.18 0.49
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(1.70) (3.88) (1.55) (0.41)
Current Ratio
4.61 5.04 2.76 1.02
Net Debt/EBITDA
1.70 6.50 1.98 (0.27)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(27.52%) 23.89% (29.06%) (96.07%)
Free Cash Flow Yield
(44.55%) (21.99%) (40.76%) (207.90%)
Free Cash Flow per Share
(0.95) (1.14) (1.90) (1.67)
Book value per Share
2.37 2.71 4.51 0.41
Free Cash Flow
(2.69) (4.46) (4.82) (1.62)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 30 Sep 2026